{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"005-766-100-657-423","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"005-766-100-657-423"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11856,"type":"PATENT","title":"University of Nebraska - Lincoln Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":2483,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8468,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
wherein R represents a substituted or unsubstituted, straight or branched chain, saturated or unsaturated hydrocarbyl (C1-C15) group, radioactive halogen, non-radioactive halogen;\n
Ra represents radioactive halogen, non-radioactive halogen, hydroxyl, one of R and Ra being radioactive halogen;\n
X represents hydrogen, non-radioactive halogen, radioactive halogen;\n
Y represents hydrogen, a straight or branched chain, substituted or unsubstituted, saturated or unsaturated hydrocarbyl (C1-C4) group, and 11C-containing analogues of said hydrocarbyl group; and\n
Z represents hydrogen, straight or branched chain, substituted or unsubstituted saturated or unsaturated hydrocarbyl (C1-C4) group, and 11C-containing analogues of said hydrocarbyl group."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The compound of claim 1, wherein R represents straight chain alkyl (C1-C8) or aryl; Ra represents 18F; X represents F; Y represents branched chain alkyl (C1-C4); Z represents branched chain alkyl (C1-C4)."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The compound 5′-O-[cycloSaligenyl-3,5-di(tert-butyl)-6-fluoro]-3′-[18F]fluoro thymidine monophosphate, according to claim 1."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The compound 5′-O-[cycloSaligenyl-3,5-di(tert-butyl)-6-fluoro-2′,3′-deoxy-3′-fluoro-5-[125I]iodouridine monophosphate, according to claim 1."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A method for making an ante mortem diagnosis of Alzheimer's disease comprising:\n
a. administering to a patient suspected of having Alzheimer's disease a compound according to claim 1 in an amount of up to 20 mCi (up to 740 MBq) effective to bind to butyrylcholinesterase (BChE) present in the brain of said patient; and\n
b. detecting the amount of BChE bound by said compound."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, further comprising comparing the amount of BChE detected to a positive or negative control."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein said detecting is carried out by imaging."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 7, wherein the imaging is positron emission tomography (PET) or single photon emission computed tomography (SPECT)."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein said compound is administered intravenously or intracarotid."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 6, wherein steps (a) and (b) are repeated at least once after passage of a predetermined time interval, an increase in said radioactive drug uptake during said time interval being indicative of the progression of AD in said patient."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method according to claim 6, wherein steps (a) and (b) are repeated at least once after passage of a predetermined time interval during which AD therapy is administered to said patient, a decrease in said radioactive drug uptake being indicative of the effectiveness of said therapy."],"number":11,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}